Fabio Puglisi

Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer

David Miles, Arlene Chan, Luc Dirix et al. · Journal of Clinical Oncology · 2010 · 881 citations

Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer

Olivia Pagani, Meredith M. Regan, Barbara Walley et al. · New England Journal of Medicine · 2014 · 738 citations · Full text

Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer

Prudence A. Francis, Olivia Pagani, Gini F. Fleming et al. · New England Journal of Medicine · 2018 · 646 citations · Full text

A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study

Jesse J. Swen, Cathelijne H. van der Wouden, Lisanne E. N. Manson et al. · The Lancet · 2023 · 462 citations · Full text

Drug Safety, Adverse Drug Reactions, Pharmacoepidemiology +9

Measures of Outcome in Metastatic Breast Cancer: Insights From a Real-World Scenario

Marta Bonotto, Lorenzo Gerratana, Elena Poletto et al. · The Oncologist · 2014 · 283 citations · Full text